论文部分内容阅读
目的:探究阿奇霉素联合多索茶碱治疗喘息性支气管肺炎患儿的临床疗效。方法:选取我院2012年1月2015年3月收治的喘息性支气管肺炎患儿87例,对照组48例患儿给予常规治疗,观察组39患儿在对照组基础上给予阿奇霉素联合多索茶碱治疗,两组患儿均治疗7 d比较两组患儿临床疗效,气促缓解,咳嗽消失和肺部哮鸣音消失时间,以及治疗前后白细胞WBC,血清C反应蛋白CRP,免疫球蛋白IgE和嗜酸粒细胞阳离子蛋白ECP水平,以及两组患儿不良反应的情况。结果:观察组和对照组患儿的临床总有效率分别为94.8%,79.2%,两组间比较有统计学差别(P<0.05)。观察组患儿气促缓解,咳嗽消失和肺部哮鸣音消失时间明显短于对照组,差异有统计学意义(P<0.05),观察组治疗后白细胞WBC,血清C反应蛋白CRP,免疫球蛋白IgE和嗜酸粒细胞阳离子蛋白ECP水平明显高于对照组,差异有统计学意义(P<0.05),对照组不良反应发生率为2.1%,与观察组不良反应发生率5.1%比较,差异无统计学意义(P>0.05)。结论:阿奇霉素联合多索茶碱治疗喘息性支气管肺炎患儿的临床疗效确切,能够快速起效,值得临床推广。
Objective: To investigate the clinical efficacy of azithromycin combined with doxofylline in the treatment of asthmatic bronchial pneumonia in children. Methods: 87 children with asthmatic bronchopneumonia admitted in our hospital from January 2012 to March 2015 were enrolled. 48 children in the control group were given routine treatment. The 39 children in the observation group were given azithromycin combined with Doxo tea Alkali treatment, the two groups of children were treated for 7 days compared the clinical efficacy of two groups of children, relief of shortness of breath, cough disappeared and disappearance of lung wheeze time, and before and after treatment of leukocytes WBC, serum C-reactive protein CRP, immunoglobulin IgE And eosinophil cationic protein ECP levels, as well as two groups of children with adverse reactions. Results: The total effective rates of the observation group and the control group were 94.8% and 79.2% respectively, with statistical difference between the two groups (P <0.05). In the observation group, the reduction of shortness of breath, disappearance of cough and disappearance of pulmonary wheeze were significantly shorter than those in the control group (P <0.05). WBC, CRP, The levels of protein IgE and eosinophil cationic protein ECP were significantly higher than those in the control group (P <0.05). The incidence of adverse reactions in the control group was 2.1%, which was 5.1% compared with the incidence of adverse reactions in the observation group No statistical significance (P> 0.05). Conclusion: Azithromycin combined with doxofylline in the treatment of asthmatic bronchopneumonia in children with definite clinical efficacy, rapid onset, worthy of clinical promotion.